terça-feira, 6 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 20, 2025

Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights

View original at globenewswire.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights Burlingame, CA, Nov…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global anti-obesity drug industry is set to experience strong growth, owing to rising prevalence of obesity, escalating health and wellness awareness, growing popularity of combination therapies, and advancements in new drug formulations

    80% confidence

  • High cost of treatment and growing competition from non-pharmacological approaches might slow down market growth to some extent during the forecast period

    80% confidence

  • GLP-1 receptor agonists like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy are revolutionizing obesity treatment

    80% confidence

  • Asia Pacific, with an estimated share of 24.2% in 2025, is anticipated to emerge as a highly lucrative market for anti-obesity drug companies

    80% confidence

  • The market will exhibit a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032

    80% confidence

  • Prescription drugs segment is slated to dominate the industry, accounting for nearly two-thirds of the global anti-obesity drug market share by 2025

    80% confidence

  • North America is expected to retain its dominance, capturing 38.3% of the global market share in 2025

    80% confidence

  • More than 1 billion people will be living with obesity by 2030

    80% confidence

  • The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032

    80% confidence

  • GLP-1 receptor agonists segment is expected to account for a market share of 22.1% in 2025

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights — Source | Via News | pt.VIA.NEWS